Novo Nordisk A/S

Diabetes and Glycaemic Control

Extensive work in type 2 diabetes and type 1 diabetes, with attention to blood glucose control, treatment intensification, and combinations involving basal insulin, GLP-1 receptor agonists, and SGLT2 inhibitors. Research also includes paediatric type 2 diabetes and diabetes-related complications.

  • HbA1c reduction
  • Insulin icodec
  • Oral semaglutide
  • Diabetic retinopathy

Clinical interest extends to metabolic control across age groups, including adolescents and children, with studies touching on diabetes management alongside excess body weight.

Obesity and Weight Management

Focused research in obesity, overweight, and related metabolic risk states, including weight reduction and long-term weight maintenance in adults, adolescents, and children. Trials also cover obesity linked with type 2 diabetes, obstructive sleep apnoea, knee osteoarthritis, and post-menopausal obesity.

  • Cagrilintide
  • CagriSema
  • Semaglutide
  • Liraglutide

Research includes metabolic and appetite-related outcomes in adults and paediatric populations with excess body weight.

Cardiovascular, Renal, and Inflammatory Disease

Work spans heart failure, acute myocardial infarction, atherosclerotic cardiovascular disease, cardiometabolic disease, and chronic kidney disease, often in the setting of systemic inflammation. Studies also include transthyretin amyloid cardiomyopathy and cardiovascular risk reduction.

  • Ziltivekimab
  • ATTR cardiomyopathy
  • Major adverse cardiovascular events
  • Chronic kidney disease progression

Therapeutic interest includes inflammatory pathways in cardiovascular and renal disease, as well as outcomes linked to cardiac function and vascular injury.

Haematology and Blood Disorders

Research activity includes inherited bleeding disorders such as haemophilia A and haemophilia B, with and without factor VIII inhibitors. Studies also address sickle cell disease and thalassaemia.

  • Concizumab
  • Mim8
  • Bleeding prevention
  • Sickle cell disease

The portfolio reflects interest in prophylaxis, bleeding control, and the management of chronic haematologic complications across adult and paediatric populations.

Endocrine, Growth, and Rare Disease Areas

Additional research covers growth hormone deficiency, short stature, Turner syndrome, Noonan syndrome, and small for gestational age children. The sponsor also studies alzheimer’s disease, non-alcoholic steatohepatitis, alcohol-related liver disease, and hereditary haemochromatosis.

  • Somapacitan
  • Paediatric growth disorders
  • NASH
  • Mild cognitive impairment

These programmes include endocrine replacement, liver disease, and neurocognitive conditions, with interest in both common metabolic and less common inherited disorders.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on the Effects of Somapacitan and Somatropin in Children with Short Stature Born Small for Gestational Age Without Catch-Up Growth by Age 2

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria France Hungary Italy Latvia
  • Study on the Effects of Semaglutide in Patients with Non-Alcoholic Steatohepatitis (NASH) and Fibrosis Stages 2 or 3

    Not recruiting

    3 1 1
    Investigated Drugs:
    Austria Belgium Bulgaria Croatia Czechia Denmark +12
  • Study on the Effectiveness of NNC0194-0499 and Semaglutide in Treating Non-Alcoholic Steatohepatitis (NASH) in Patients with Fibrosis Stages 2-4

    Not recruiting

    2 1
    Belgium Bulgaria Czechia Denmark France Germany +5
  • Study on the Effects of Somapacitan and Somatropin in Children with Growth Hormone Deficiency

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria France Germany Italy Latvia Poland +2
  • Study on the Effectiveness and Safety of Oral Semaglutide Compared to Placebo in Children and Adolescents with Type 2 Diabetes Using Metformin or Basal Insulin

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Czechia Greece The Netherlands Portugal Romania
  • Study on the Effectiveness of Decitabine and Tetrahydrouridine in Patients with Sickle Cell Disease Not Eligible for Hydroxyurea Treatment

    Not recruiting

    2 1 1
    Investigated Diseases:
    France Greece Italy Spain